A Novel Multi-strain Vaginal Synbiotic is Effective in Optimizing the Vaginal Microbiome: Results from a Randomized, Placebo-controlled Clinical Trial

Jacques Ravel,Eleni Greenwood Jaswa,Sara Gottfried,Miriam Greene,Susan Kellogg-Spadt,Dirk Gevers,Diane Harper
DOI: https://doi.org/10.1101/2024.05.20.24307554
2024-05-21
Abstract:This research letter describes the results of a clinical trial of a novel vaginal synbiotic comprising three L. crispatus strains and a supportive nutrient complex. Results indicated that administration of the synbiotic led to an optimal vaginal microbiome dominated by L. crispatus (CST I) and additionally reduced the abundance of microbes associated with vaginal dysbiosis and the abundance of Candida, the most common source of vaginal yeast infections.
What problem does this paper attempt to address?
This paper investigates the effect of a novel multi-strain vaginal probiotic (VS-01) on optimizing the vaginal microbiota. In a randomized, placebo-controlled clinical trial, researchers found that this probiotic significantly increased the relative abundance of L. crispatus and reduced the microbial abundance associated with vaginal dysbiosis and Candida (a common source of vaginal fungal infections). The trial showed that among participants with baseline vaginal dysbiosis, the use of VS-01 vaginal suppositories transformed the microbiota into an optimal classification group dominated by L. crispatus (CST I) with a conversion rate of 90%, compared to only 11% in the placebo group. Furthermore, VS-01 also decreased the average abundance of Candida and bacteria associated with vaginal dysbiosis, such as Gardnerella, and the abundance of sialidase genes that potentially disrupt the protective mucus barrier, while reducing the levels of the pro-inflammatory cytokine IL-1ɑ. Therefore, this study provides the first evidence that a multi-strain vaginal probiotic can effectively establish a protective vaginal microenvironment and have a positive impact on improving women's health conditions.